Myriad Genetics (MYGN) Tops Q4 EPS by 3c, provides guidance

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $196.6 million versus the consensus estimate of $194.8 million.

GUIDANCE:

Myriad Genetics sees FY2024 EPS of $0.00-$0.05, versus the consensus of ($0.02). Myriad Genetics sees FY2024 revenue of $820-840 million, versus the consensus of $834 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Tesla Q2 deliveries: What to expect from the critical report
• Bernstein SocGen on UnitedHealth Group (UNH): 'Expecting a strong 2Q driven by MA and potential for guidance raise'